公开(公告)号：US20170008841A1

公开(公告)日：2017-01-12

申请号：US15273555

申请日：2016-09-22

Applicant: DSM IP ASSETS B.V.

Inventor： Jingfei GUO ,  Matthew J. JONES ,  Christian SCHAEFER ,  Joachim ULRICH ,  Viviane VERLHAC-TRICHET

IPC: C07C403/24 ,  A23K50/80 ,  A23K20/179 ,  A61K9/00

CPC classification number: C07C403/24 ,  A23K20/179 ,  A23K50/80 ,  A23L5/44 ,  A61K9/0056 ,  C07B2200/13 ,  Y02A40/818

Abstract: The invention describes previously undisclosed crystal forms of astaxanthin designated crystal form I and II. It has been surprisingly found that the two crystal forms of astaxanthin show an improved bioavailability, a relatively high solubility in specific organic solvents and an increased long-term stability. For example the new forms are stable in solid form for at least 90 days at a temperature of 20° C.-40° C. It was further found that the two crystal forms can be prepared from each other. Therefore the invention also relates to methods for preparing said crystal forms. In addition, the invention relates to administration forms (hereinafter also called “formulations”) comprising one of the two crystal forms according to the invention or mixtures thereof dissolved or suspended in oil or organic-solvent.

Abstract translation: 本发明描述了以前未公开的虾青素晶体形式，其指定为I型和II型晶体。 已经令人惊讶地发现，两种虾青素的晶体形式具有改善的生物利用度，在特定的有机溶剂中的相对较高的溶解度和增加的长期稳定性。 例如，新的形式在20℃-40℃的温度下以固体形式稳定至少90天。进一步发现，两种晶型可以彼此制备。 因此，本发明还涉及制备所述晶形的方法。 此外，本发明涉及包含根据本发明的两种晶型之一或其溶解或悬浮在油或有机溶剂中的混合物的给药形式（以下也称为“制剂”）。

公开(公告)号：US20140221694A1

公开(公告)日：2014-08-07

申请号：US14245930

申请日：2014-04-04

Applicant: DSM IP ASSETS B.V.

Inventor： Jingfei GUO ,  Matthew J. JONES ,  Christian SCHAEFER ,  Joachim ULRICH ,  Viviane VERLHAC-TRICHET

IPC: A23K1/16 ,  A23K1/18

CPC classification number: C07C403/24 ,  A23K20/179 ,  A23K50/80 ,  A23L5/44 ,  A61K9/0056 ,  C07B2200/13 ,  Y02A40/818

Abstract: The invention describes previously undisclosed crystal forms of astaxanthin designated crystal form I and II. It has been surprisingly found that the two crystal forms of astaxanthin show an improved bioavailability, a relatively high solubility in specific organic solvents and an increased long-term stability. For example the new forms are stable in solid form for at least 90 days at a temperature of 20° C.-40° C. It was further found that the two crystal forms can be prepared from each other. Therefore the invention also relates to methods for preparing said crystal forms. In addition, the invention relates to administration forms (hereinafter also called “formulations”) comprising one of the two crystal forms according to the invention or mixtures thereof dissolved or suspended in oil or organic-solvent.

Abstract translation: 本发明描述了以前未公开的虾青素晶体形式，其指定为I型和II型晶体。 已经令人惊讶地发现，两种虾青素的晶体形式具有改善的生物利用度，在特定的有机溶剂中的相对较高的溶解度和增加的长期稳定性。 例如，新的形式在20℃-40℃的温度下以固体形式稳定至少90天。进一步发现，两种晶型可以彼此制备。 因此，本发明还涉及制备所述晶形的方法。 此外，本发明涉及包含根据本发明的两种晶型之一或其溶解或悬浮在油或有机溶剂中的混合物的给药形式（以下也称为“制剂”）。